ArticleCureus2026
Prevalence of Adverse Effects Among Prostate Cancer Patients Following Robotic-Assisted Laparoscopic Prostatectomy, External Beam Radiation Therapy, or Combined Therapy in North Florida.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRobotic-assisted laparoscopic prostatectomy (RALP) and external beam radiation therapy (EBRT) are two widely recognized clinical standards for treating localized prostate cancer (PCa). This study aims to investigate the prevalence of various post-treatment side effects after RALP, EBRT, and the combination of RALP followed by EBRT.
methodsThis retrospective study utilized a large-scale bioinformatics database through the UF Health Integrated Data Repository, Informatics for Integrating Biology and the Bedside (i2b2 1.7.12a PROD). Males over the age of 35 with PCa who underwent RALP, EBRT, or RALP followed by EBRT were identified. Participants who received other treatments for PCa were excluded. International Classification of Diseases (ICD)-9, ICD-10, and Current Procedural Terminology (CPT) codes were used to identify patients with PCa and post-treatment side effects, while CPT codes were used to isolate those who underwent RALP, EBRT, or RALP followed by EBRT. Patients diagnosed with a given complication before receiving treatment were excluded from the analysis. SPSS was used for all statistical analyses, which consisted of multiple independent chi-square tests. Percentages for each postoperative complication were calculated using the total number of participants who received each treatment.
resultsA total of 2329576 patients were identified from June 2011 to December 2024. Of these, 752491 were males over 35 years old. Among 17729 patients with PCa, 1148 (6.48%) received RALP, 1399 (7.89%) underwent EBRT, and 144 (0.81%) underwent RALP followed by EBRT. The most common side effects in men who underwent RALP were stress incontinence, 690 (60.10%); erectile dysfunction, 567 (49.39%); and gross hematuria, 63 (5.49%). The most common side effects in men who underwent EBRT were erectile dysfunction, 157 (11.22%); gross hematuria, 118 (8.43%); and pelvic pain, 67 (4.79%). The most common side effects in men who underwent RALP followed by EBRT were erectile dysfunction, 142 (98.61%); stress incontinence, 22 (15.28%); and gross hematuria, 21 (14.58%). Gross hematuria, bladder cancer, and prostate-specific antigen (PSA) elevation were significantly more likely in patients who underwent EBRT. Stress incontinence and erectile dysfunction were significantly more common in patients who underwent RALP.
conclusionEach treatment modality differs in its postoperative complication profile. Further investigation of these findings is needed to better assess treatment risks and guide physician decision-making for optimal patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.